

Cite this: *Chem. Sci.*, 2023, 14, 5945

All publication charges for this article have been paid for by the Royal Society of Chemistry

Regulation of the CRISPR-Cas12a system by methylation and demethylation of guide RNA†

Zhian Hu,^{ab} Ao Sun,^c Jinlei Yang,^b Gul Naz,^{id b} Gongwei Sun,^b Zhengping Li,^{id a} Jun-Jie Gogo Liu,^{*cd} Sichun Zhang^{id *b} and Xinrong Zhang^{id *b}

Chemical modifications of CRISPR-Cas nucleases help decrease off-target editing and expand the biomedical applications of CRISPR-based gene manipulation tools. Here, we found that epigenetic modifications of guide RNA, such as m6A and m1A methylation, can effectively inhibit both the *cis*- and *trans*-DNA cleavage activities of CRISPR-Cas12a. The underlying mechanism is that methylations destabilize the secondary and tertiary structure of gRNA which prevents the assembly of the Cas12a-gRNA nuclease complex, leading to decreased DNA targeting ability. A minimum of three adenine methylated nucleotides are required to completely inhibit the nuclease activity. We also demonstrate that these effects are reversible through the demethylation of gRNA by demethylases. This strategy has been used in the regulation of gene expression, demethylase imaging in living cells and controllable gene editing. The results demonstrate that the methylation-deactivated and demethylase-activated strategy is a promising tool for regulation of the CRISPR-Cas12a system.

Received 6th February 2023

Accepted 8th May 2023

DOI: 10.1039/d3sc00629h

rsc.li/chemical-science

Introduction

Clustered regularly interspaced short palindromic repeats (CRISPR) – Cas technologies have revolutionized fields ranging from fundamental science to medical therapies.^{1,2} However, challenges of spatial and temporal control of CRISPR-Cas need to be addressed, which reduces potential off-target editing and broadens medical applications. Exogenously inducible CRISPR-Cas tools have been first developed,³ such as employing blue light^{4,5} and small drug molecules^{6–8} to precisely activate the CRISPR-Cas system to induce interest gene expression. To fully exert the potential of CRISPR in living cells, CRISPR tools need to be manipulated using crucial endogenous biomolecules for studying intracellular biomarkers and controlling the genome of specific cells such as cancer cells and stem cells.^{9,10} For example, a microRNA-inducible CRISPR platform has been proposed for serving as a stem cell genome-regulation tool and sensing the microRNA.⁹

Chemical modifications on gRNA can also efficiently regulate the performance of CRISPR-Cas.^{8,11–13} Many chemical modifications on ribose sugar and the backbone have been investigated so far, including 2'-F,^{14,15} universal bases (inosine and 5' nitroindole),¹⁶ locked nucleic acid (LNA),¹⁷ phosphorothioates (PS),¹⁸ *etc.* These chemical modifications could significantly reduce off-target editing and strengthen CRISPR-Cas system bioavailability *in vivo*. Recently, conditional control of chemical modifications on gRNA, such as light caged modifications^{19–21} and small-ligand caged modifications,^{8,22} has sprung up. For example, Deiters' group has achieved light-controllable gene editing in living cells and zebrafish through 6-NPOM-caged modifications on gRNA of Cas9.¹³ These modifications can further spatiotemporally control CRISPR *in vivo* for precise gene-editing and regulation. Despite the achievements, existing chemical modifications are commonly artificial rather than natural intracellular RNA modifications, which are scarcely related to cellular behaviours, such as epigenetic regulation.¹⁰ In general, endogenous chemical modifications, such as methylation, are often associated with vital cellular processes.²³ By exploiting endogenous reversible chemical modifications to regulate the activity of CRISPR systems, we may be able to minimize their off-target effects while conferring them with cell-type or cell-state specificity, and even apply them for biosensing and therapeutic applications. Therefore, it is promising to investigate endogenous chemical modifications on gRNA to control CRISPR-Cas.¹²

The CRISPR-Cas effector is similar to the ribosome, working as ribonucleoprotein particles (RNPs).^{24,25} Emerging evidence demonstrates that epigenetic modifications on the RNA

^aBeijing Key Laboratory for Bioengineering and Sensing Technology, School of Chemistry and Biological Engineering, University of Science and Technology Beijing, 30 Xueyuan Road, Haidian District, Beijing 100083, P. R. China

^bDepartment of Chemistry, Tsinghua University, Beijing 100084, P. R. China. E-mail: xrzhang@mail.tsinghua.edu.cn; sczhang@mail.tsinghua.edu.cn

^cTsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, P. R. China. E-mail: junjielogoliu@mail.tsinghua.edu.cn


^dBeijing Advanced Innovation Center for Structural Biology & Frontier Research Center for Biological Structure, School of Life Sciences, Tsinghua University, Beijing 100084, P. R. China

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3sc00629h>



component can precisely regulate the function and structure of RNPs, playing an essential role in almost every aspect of cellular regulation and growth.^{26–28} Among these RNA epigenetic markers, N₆-methyladenosine (m6A) and N₁-methyladenosine (m1A) are two of the few RNA modifications whose reversible reaction pathway in cells has been fully elucidated.²⁹ m6A could be erased from RNA by ALKBH5 and FTO demethylases while m1A could be removed by ALKBH3 demethylase.^{30–32} These demethylases maintain dynamic m6A and m1A expression in living cells and play vital roles in promoting cell proliferation and regulating RNA-protein interactions.³³ Furthermore, regulation of CRISPR activity by naturally occurring mRNA modifications has scarcely been systematically studied before. Therefore, we expect that methylation and demethylation of CRISPR gRNA may be an effective way to control the activity of the CRISPR system when combined with demethylases.

In this work, we found that the m6A or m1A modification in the 5' handle of gRNA could significantly inhibit the *cis*- and *trans*-cleavage activity of CRISPR-Cas12a. Referring to the structure of the Cas12a effector,³⁴ methylation may hinder or disrupt the pseudoknot structure of gRNA, which prevents the formation of a stable complex between the Cas12a protein and gRNA, resulting in the loss of DNA cleavage capability. The gRNA structure could be restored by demethylases through erasing the methyl group. The m6A methylation-deactivated CRISPR-Cas12a nuclease can be robustly reactivated by ALKBH5 and FTO, while the m1A methylation-deactivated CRISPR-Cas12a can be reactivated by ALKBH3 demethylases. Using the *trans*-cleavage activity of Cas12a, we were able to successfully develop a reliable and sensitive fluorescence read-out strategy for monitoring the activity of demethylases. Moreover, we successfully used the demethylase to control gene editing. In addition, we constructed a specific dCas12a transcriptional circuit that permits inducible protein expression in living cells by demethylase-mediated gRNA activation. Overall, we proposed a novel strategy for manipulating CRISPR-Cas12a activity by controlling chemical modifications of gRNA (Scheme 1).



Scheme 1 Illustration of a methylation-deactivated and demethylase-activated CRISPR-Cas12a system. m6A or m1A in the 5' handle of gRNA disrupts the interaction between the Cas12a protein and gRNA. The deactivated CRISPR-Cas12a could be reactivated by demethylases. This strategy has enabled the *in vitro* and *in vivo* development of biosensors for demethylases and the precise regulation of gene expression.

Results and discussion

The effects of m6A modifications on the cleavage activity of CRISPR-Cas12a

As a proof of concept, the effect of m6A modification on different regions of gRNA has been investigated in detail. As shown in Fig. 1A, the 5' handle pseudoknot structure of gRNA (red box) is tightly folded and particularly sensitive to chemical modifications.¹² The remaining 20 nts of the gRNA (blue box) serve as the spacer that recognizes and invades the target dsDNA. Both regions of the gRNA are important for efficient DNA cleavage. Generally, the methyl group in m6A causes a steric clash in Watson–Crick pairing of RNA (Fig. 1B).^{26,35} Therefore, we expect that this modification may destabilize the pseudoknot structure or the pairing between the spacer and target DNA. We constructed BC-gRNA (Fig. 1C) containing m6A at sites A₂, A₈, A₁₆, and A₁₈. As for the spacer, BR-gRNA (Fig. 1C) with m6A at sites A₂₂, A₂₇, A₃₁, and A₃₆ was designed. In addition, a gRNA with eight m6A methylations (8(m6A)-gRNA) was designed to effectively switch-off CRISPR-Cas12a (Fig. 1C).




Fig. 1 The effects of m6A modifications in gRNA on DNA cleavage activity of CRISPR-Cas12a. (A) The secondary structure of gRNA. The red box represents the 5' handle of gRNA and the blue box denotes the spacer sequence of gRNA. (B) The chemical structure of m6A modification. (C) Locations of m6A modifications in different gRNAs are illustrated. (D) Agarose electrophoresis indicates the results of CRISPR-Cas12a *cis*-cleavage. (Lane 1) Only the dsDNA target; (Lane 2) non-modified gRNA + dsDNA + Cas12a; (Lane 3) BR-gRNA + dsDNA + Cas12a; (Lane 4) BC-gRNA + dsDNA + Cas12a; (Lane 5) 8(m6A)-gRNA + dsDNA + Cas12a. (E) Time course of Cas12a with different gRNA *trans* cleaving FQ probes.



Generally, CRISPR-Cas12a holds two cleavage activities including target specific cleavage (*cis*-cleavage) activity and non-specific nucleic acid cleavage (*trans*-cleavage) activity. In this work, we conducted separate tests to assess the impact of methylated gRNAs on two discrete activities of CRISPR-Cas12a. First, the *cis*-cleavage activity of Cas12a to the dsDNA substrate was investigated. Gel electrophoresis revealed that dsDNA could be effectively cleaved by Cas12a in the presence of normal gRNA (Fig. 1D). BR-gRNA displayed a slight inhibitory effect on *cis*-cleavage. However, *cis*-cleavage activity decreased significantly when the gRNA was replaced by BC-gRNA, and few dsDNA substrates were cleaved. Actually, BC-gRNA has an inhibitory effect comparable to that of 8(m6A)-gRNA. These results demonstrate that m6A modification in the 5' handle region of gRNA inhibited *cis*-cleavage of CRISPR-Cas12a significantly more than that in the 3' spacer region of gRNA. We further investigated the inhibitory effect of m6A modification on the *trans*-cleavage activity of CRISPR-Cas12a. To monitor the *trans*-cleavage activity of Cas12a, a dually labelled substrate FQ-DNA probe was often used (5' FAM and 3' BHQ-1, Table S3[†]). The *trans*-cleavage would remove the quencher from the fluorophore on the FQ probe, resulting in fluorescence recovery. As shown in Fig. 1E, the m6A inhibition pattern during *trans*-cleavage was comparable to that of *cis*-cleavage. In comparison to natural gRNA, BR-gRNA could slightly suppress the *trans*-activity of Cas12a, with an inhibition rate of about 40%. Notably, BC-gRNA has a stronger inhibitory ability, with *trans*-cleavage activity decreasing by more than 70%. In addition, the *trans*-cleavage ability of Cas12a can be activated by a ssDNA activator (Fig. S2A[†]). As shown in Fig. S2B and C,[†] significant inhibition of *trans*-cleavage was also achieved by m6A in the 5' handle of the gRNA using ssDNA as the activator.

Since m6A modification brings a significant inhibition effect to CRISPR-Cas12a activity, we further systematically investigated the m6A position in the 5' handle region for the deactivation of Cas12a. As shown in Fig. 2A, the methyl group was modified at the second to fifth adenine N₆ site in the 5' handle of gRNA, respectively (m6A₂, m6A₃, m6A₄, and m6A₅). For *cis*-cleavage, there was no significant difference between natural gRNA and single-m6A modified gRNAs (Fig. 2B, Lane 2–6). Instead, m6A_{all}-gRNA showed minimal cleavage activity (Fig. 2B, Lane 7). Additionally, the inhibitory effect on *trans*-cleavage activity was investigated. The suppression patterns of dsDNA and ssDNA activators were consistent as shown in Fig. 2C and S3B.[†] It is difficult to deactivate CRISPR-Cas12a *trans*-cleavage by modifying gRNA with a single m6A. These findings show that the deactivation of CRISPR-Cas12a relies on the synergetic effect of multiple m6A modifications on the pseudoknot structure. Notably, m6A modifications at the sites A₃, A₄, and A₅ have a stronger inhibitory effect than at the A₂ site. The m6A modifications at the above three positions may play a vital role in deactivating CRISPR-Cas12a.

CRISPR-Cas12a deactivation is dependent on the number of m6A modifications on gRNA. Three gRNAs termed m6A_{3,4}-gRNA, m6A_{3,4,5}-gRNA and m6A_{all}-gRNA were designed as shown in Fig. 2D. The inhibitory effects on *cis*-cleavage were positively correlated with the number of m6A modifications (Fig. 2E).




Fig. 2 Systematic screening of the position and number of m6A in the 5' handle of gRNA. (A) and (D) Locations of m6A modification in different gRNAs. (B) and (C) Screening of the position of m6A in the 5' handle of gRNA. (B) Agarose gel electrophoresis (2%) characterized *cis*-cleavage. (Lane 1) Only the dsDNA target; (C) fluorescence results of *trans* cleaving the FQ-probe. (E) and (F) Screening the number of m6A in the 5' handle. (E) Agarose gel electrophoresis (2%) characterized *cis*-cleavage. (Lane 1) Only the dsDNA target; (Lane 2) natural gRNA; (F) fluorescence results of *trans* cleaving the FQ-probe. The red column represents CRISPR-Cas12a with normal gRNA. The blue column represents CRISPR-Cas12a with m6A-modified gRNA. The error bar represents the standard deviation of three measurements.

Among all designs, m6A_{3,4,5}-gRNA was the most effective at inhibiting the *cis*-cleavage activity of CRISPR-Cas12a. Next, we investigated whether m6A_{3,4,5}-gRNA could efficiently repress the *trans*-cleavage of Cas12a. The results of *trans*-cleavage are shown in Fig. 2F, S3D and S18.[†] The fluorescence results indicate that the *trans*-cleavage activity decreased with increasing m6A modifications on gRNA. Together, the m6A modification in the 5' handle of gRNA has a similar inhibitory pattern on both the *cis*- and *trans*-cleavages. The cleavage activity of CRISPR-Cas12a can be efficiently deactivated by m6As at the three sites A₃, A₄, and A₅ of the gRNA pseudoknot structure.

The deactivation mechanism of m6A modified gRNA was further tentatively studied using the previously reported atomic models of Cas12a effectors.³⁴ As shown in Fig. 3A, Cas12a nuclease forms an open "thread cutter" architecture. The 5' handle of gRNA is located at the hub of the "thread cutter". The details of the 5' handle are shown in Fig. 3B and C, and this pseudoknot structure is located in a pocket-like domain of Cas12a nuclease. Through multi-specific interactions with the Cas12a protein, the gRNA pseudoknot functions as a key structural element to recruit Cas12a, promote conformational-






Fig. 3 The analysis of the underlying inhibitory mechanism. (A) Crystal structure of the Cas12a-gRNA-dsDNA complex (Cas12a is shown as a grey surface model, and gRNA is marked in red). The 5' handle of gRNA is denoted by a blue box. (PDB: 5XUZ) (B) The details of the 5' handle in the Cas12a-gRNA-dsDNA complex. The Cas12a protein is marked in cyan and gRNA is marked in red. (C) The tertiary structure of the 5' handle of gRNA. (D) The electrophoretic mobility shift assay (EMSA) picture (native 4% PAGE). The varying concentrations of Cas12a were incubated with 3' labelled FAM gRNA (left graph, 20 nM) or 3' labelled FAM m6A₃₄₅-gRNA (right graph, 20 nM) respectively. The ratios listed represent the concentrations of Cas12a: the concentrations of gRNA.

state transitions, and activate the nuclease activity of Cas12a.^{18,36} Previous research has indicated that the N₆-methyl group could weaken the stability of the RNA secondary structure.³⁷ We hypothesize that the m6A modifications in the 5' handle may disrupt the interaction between gRNA and the Cas12a protein, thereby leaving Cas12a in a non-active state. To test this hypothesis, an electrophoretic mobility shift assay (EMSA) was used to determine the binding affinity between m6A modified gRNA and Cas12a. In this assay, the comigration ability of 3' FAM labelled gRNA (Table S1†) at a 10 nM concentration was compared to the Cas12a concentration ranging from 0 to 80 nM (protein to RNA ratio from 0 : 1 to 8 : 1). We gradually increased Cas12a nuclease concentrations while maintaining constant gRNA levels. As shown in Fig. 3D, although normal gRNA began to shift at a protein to RNA ratio of 1 : 1, modified gRNA hardly shifted even at an 8 : 1 protein to RNA ratio. M6A modified gRNA requires more Cas12a protein for functional RNP assembly than natural gRNA. Furthermore, we systematically investigated the molecular interactions in the 5' handle of gRNA to comprehend this inhibitory effect (Fig. S4 and S5†). Consistent with the aforementioned hypothesis, m6A in the 5' handle suppressed gRNA's capacity to bind the Cas12a protein.

The inhibitory effect of m1A modification on CRISPR-Cas12a

In addition to m6A methylation, m1A is a well-characterized RNA modification containing a methyl group at the first nitrogen of adenosine and could entirely disrupt the Watson-Crick pairing

between A and U (Fig. 4A). This chemical modification should therefore have a stronger inhibitory effect on CRISPR-Cas12a than m6A. The m1A-modified gRNAs were also evaluated (Fig. 4B). For *cis*-cleavage, m1A at the site A₂ shows minimal inhibition which is consistent with m6A (Fig. 4C Lane 3). But the m1A at the site A₃, A₄, or A₅ can significantly inhibit the activity of CRISPR-Cas12a (Fig. 4C Lane 4–6). When the sites A₃, A₄, and A₅ were simultaneously modified with m1A, no products were observed, indicating that the *cis*-cleavage activity of CRISPR-Cas12a was nearly entirely suppressed (Fig. 4C Lane 8). In addition, m1A has a comparable inhibitory effect on *trans*-cleavage as it does on *cis*-cleavage (Fig. 4D and S6†). The most effective CRISPR-Cas12a inhibition was achieved by simultaneously locating m1A on sites A₃, A₄, and A₅. The inhibitory effect of m1A exceeds 90% for both *cis*- and *trans*-cleavage, which is significantly higher than that of m6A modification. The mechanism of the inhibitory effect of m1A on CRISPR-Cas12a was subsequently investigated. We first used EMSA to examine the interaction between Cas12a and m1A modified gRNA. As shown in Fig. 4E, when the ratio of Cas12a to gRNA was 8 : 1, the normal gRNA was almost fully comigrated with Cas12a. However, for m1A-modified gRNA, there were few RNPs. The binding affinity of gRNA to Cas12a is significantly decreased by the m1A modification. In addition, the 3D-structural details were also evaluated. Fig. S7† demonstrates that the m1A modification at the sites A₃, A₄, and A₅ prevented adenines and uracil from forming stable Watson-Crick base-pairing, hence directly destroying the pseudoknot structure of gRNA.

The m1A modified adenine lost its ability to form hydrogen bonds with nearby uracil, which is similar to a single-base mismatch at adenosine.³⁸ Generally, mismatches between paired gRNA and the DNA target, particularly in the 5-bp PAM-proximal “seed region”, can significantly inhibit the *cis*- and *trans*-cleavage behavior of CRISPR-Cas12a.³⁹ Thus, we further investigated the inhibitory effect of m1A on the spacer sequence in detail. As shown in Fig. 5A, we designed three gRNAs with the m1A modification evenly distributed across the spacer sequence (m1A₁ is in the “seed region”; m1A₃ is adjacent to the “seed region”; m1A₆ is far away from the “seed region”). Surprisingly, for the dsDNA activator, all three m1A modified gRNAs effectively deactivated both *cis*- and *trans*-cleavage activity of CRISPR-Cas12a with nearly comparable inhibitory efficiency (Fig. 5B and C). For the ssDNA activator, m1A₆-gRNA inhibits *trans*-cleavage significantly less than m1A₁- and m1A₃-gRNA (Fig. 5D). In general, the “seed region” is highly sensitive to mismatches, but the sequence near the 3' end of the gRNA tolerates single-based mismatches.^{40,41} Consequently, m1A₁- and m1A₃-gRNA should have exhibited more inhibitory efficiency than m1A₆-gRNA; rather, dsDNA activators behaved unusually. We hypothesized that m1A on the spacer sequence may inhibit the dsDNA unwinding and R-Loop conformational-state transitions^{16,42} in the cleavage process, except for preventing Watson-Crick pairing.

Re-activating methylation-deactivated CRISPR-Cas12a via demethylases

Typically, the ALKBH5 demethylase can effectively remove m6A modifications on RNA. As shown in Fig. 6, the recovery of *cis*-






Fig. 4 Systematic investigation of the m1A inhibition effect on CRISPR-Cas12a. (A) m1A destructing the Watson–Crick pairing between the adenine base (left) and uracil base (right). (B) The position and number of m1A in the 5' handle of gRNA. (C) Gel electrophoresis (2%) result of *cis* cleavage. (Lane 1) Only the dsDNA target; (Lane 2) natural gRNA (50 nM); (Lane 3) m1A₂-gRNA (50 nM); (Lane 4) m1A₃-gRNA (50 nM); (Lane 5) m1A₄-gRNA (50 nM); (Lane 6) m1A₅-gRNA (50 nM); (Lane 7) m1A₃₄-gRNA (50 nM); (Lane 8) m1A₃₄₅-gRNA (50 nM); (D) fluorescence intensity at 525 nm after *trans* cleaving the FQ-probe (1 μM). The error bar represents the standard deviation of three measurements. (E) Fluorescence images of gel shift assays. The constant concentration of gRNA is 20 nM. And the ratios were calculated using the concentration of Cas12a: the concentration of gRNA.

cleavage was characterized by gel electrophoresis and the *trans*-cleavage was monitored by fluorescence assay. Fig. 6B shows that the *cis*-cleavage ability of CRISPR-Cas12a was successfully reactivated following ALKBH5 treatment. In addition, the fluorescence studies have shown that ALKBH5 activated *trans*-cleavage as well. The fluorescence intensity of ALKBH5-treated m6A₃₄₅-gRNA (Fig. 6C line c) could recover to the same level as that of natural gRNA (Fig. 6C line a). ALKBH5, Cas12a protein, and dsDNA target were incubated without gRNA as a negative control. As expected, there were no dsDNA cleavage products and fluorescence signals (Fig. 6B lane d and Fig. 6C line d). To demonstrate the ALKBH5-mediated demethylation, the ALKBH5-treated m6A₃₄₅-gRNA was hydrolyzed by P1 nuclease, and the hydrolysates were subsequently analyzed using HPLC-MS/MS. As shown in Fig. 6D and E, the amount of guanine (G) in m6A₃₄₅-gRNA following ALKBH5 treatment remained unchanged. In contrast, the amount of m6A was significantly reduced compared to when ALKBH5 was absent. Overall, these results indicated that ALKBH5 reactivates deactivated CRISPR-Cas12a by demethylation of m6A-modified gRNA. Additionally, FTO is a well-characterized m6A demethylase. FTO demethylase has also been shown to restore m6A-deactivated CRISPR-Cas12a (Fig. S8†). We further attempted to activate the m1A-deactivated gRNA using ALKBH3 demethylase. As shown in Fig. S9,† m1A-deactivated CRISPR-Cas12a exhibited remarkable dsDNA *cis*-cleavage and ssDNA

trans-cleavage abilities in the presence of ALKBH3 demethylase. Furthermore, the HPLC-MS/MS results revealed that m1A₃₄₅-gRNA underwent a distinct demethylation process following ALKBH3 treatment (Fig. S9D†). Therefore, we successfully developed a demethylase-inducible CRISPR-Cas12a (DIC-Cas12a) strategy and found that both m6A- and m1A-deactivated CRISPR-Cas12a can be efficiently restored by demethylases.

Typical application of DIC-Cas12a based on *trans*-cleavage

The remarkable response of demethylases encouraged us to employ methylation-deactivated CRISPR-Cas12a for some potential applications. First, we intended to develop a fluorescence sensor for demethylase detection by *trans*-cleavage of CRISPR-Cas12a. Our demethylase biosensor consisted of methylated gRNA, the Cas12a protein, an ssDNA activator, and an ssDNA FQ probe. In the presence of demethylase, the methylated gRNA refolds structurally and binds to the ssDNA activator and Cas12a. In this case, CRISPR-Cas12a can be activated to cleave the FQ probes in a *trans* pattern, resulting in a continuous increase in fluorescence. The typical ALKBH5 demethylase was first measured. The concentrations of m6A₃₄₅-gRNA were optimized for exceptional analytical performance (Fig. S10†). Then, fluorescence dynamic curves were established by detecting different concentrations of ALKBH5 (Fig. 7A). The fluorescence






Fig. 5 The deactivation of CRISPR-Cas12a *cis*- and *trans*-cleavage by m1A modifications in the gRNA 3' spacer sequence. (A) The position of m1A in the gRNA spacer sequence. (B) The deactivation of CRISPR-Cas12a *cis*-cleavage. (Lane 1) Only the dsDNA target; (Lane 2) natural gRNA; (Lane 3) m1A₁-gRNA; (Lane 4) m1A₃-gRNA; (Lane 5) m1A₆-gRNA. (C) For the dsDNA activator, the deactivation of CRISPR-Cas12a *trans*-cleavage by m1A modification. (D) For the ssDNA activator, the deactivation of CRISPR-Cas12a *trans*-cleavage by m1A modification. (Left graph) The fluorescence spectra result of CRISPR-Cas12a *trans* cleaving the FQ probe. (Right graph) Inhibitory efficiency of *trans*-cleavage activity. The error bars show the standard deviation of three parallel experiments. *n.s.* represents no significant differences and $***P < 0.001$ was calculated by Student's *t*-test.

intensity increased dose-dependently from 0 nM to 300 nM for demethylases (Fig. 7B), with a good linear correlation and limit of detection (LOD). The LOD was about 0.417 nM (the concentrations corresponding to a signal 3 SD above the mean of 11 replicates of the zero calibrator). We also used this strategy to develop the FTO demethylase sensor as shown in Fig. S12.† Additionally, the m1A-deactivated CRISPR-Cas12a system was used to detect ALKBH3 demethylase (Fig. 7D and S11†). The calibration curve regression equation was derived from the range of 200–800 nM, and the LOD for ALKBH3 was 97.5 nM (Fig. 7E). The LODs of the above demethylases were comparable to or even superior to those of the reported method, and there were no laborious washing procedures or antibody incubation procedures, compared with the traditional ELISA strategy.^{43–45} Additionally, the selectivity of this strategy was assessed. The methylated gRNA was pretreated using endogenous proteins and small molecules respectively, including bovine serum albumin (BSA), polynucleotide kinase (PNK), and adenosine triphosphate




Fig. 6 Activating m6A-deactivated CRISPR-Cas12a through demethylases. (A) Schematic illustration. The dsDNA was a substrate of *cis*-cleavage. And the *trans*-cleavage was monitored by fluorescence. (B) Activation of CRISPR-Cas12a *cis*-cleavage (2% agarose gel). (Lane 1) Only the dsDNA target; (Lane a) natural gRNA + Cas12a + dsDNA; (Lane b) m6A₃₄₅-gRNA + Cas12a + dsDNA target; (Lane c) ALKBH5 demethylase + m6A₃₄₅-gRNA + Cas12a + dsDNA target; (Lane d) negative control, ALKBH5 demethylase + Cas12a + dsDNA target. (C) Activation of CRISPR-Cas12a *trans*-cleavage. The experimental details of (a)–(d) were the same as those of (B) and the FQ probe was joined in these groups respectively. (D) and (E) The results of HPLC-MS/MS demonstrated that ALKBH5 demethylase removed m6A modification on gRNA. The mother ion of the G base is 284.1 *m/z* and the specific fragmental ion is 152.1 *m/z* in mass spectrometry. The mother ion of m6A is 282.1 *m/z* and the specific fragmental ion is 150.2 *m/z*. Error bars show the standard deviation of three parallel experimental groups. $***P < 0.001$ was obtained by Student's *t*-test.

(ATP). Fig. 7C and F show that the fluorescence response was highly selective for demethylases compared with other interferences. Collectively, these findings demonstrated that the DIC-Cas12a strategy offers a novel approach for expanding the bioanalytical applications of CRISPR-Cas systems.

Controllable gene editing based on the levels of cellular demethylases

In addition to *in vitro* sensors, we tentatively used the DIC-Cas12a system to knock down the endogenous gene. We chose the *VEGAF* loci in the HEK293 cell line as target for gene editing and the sequence of gRNA followed some literature studies.⁴⁶ In general, if the CRISPR-Cas12a system works well, double-stranded breaks can be repaired by the non-homologous end-joining (NHEJ) pathway to induce random insertions and deletions (indels).






Fig. 7 Demethylase sensor based on *trans*-cleavage ability of the DIC-Cas12a system. (A) Fluorescence signal increased as the concentrations of ALKBH5 increased ((a) 300 nM; (b) 240 nM; (c) 150 nM; (d) 60 nM; (e) 15 nM; (f) 6 nM; (g) 1.5 nM; (h) 0.6 nM; (i) 0; m6A₃₄₅-gRNA: 25 nM). (B) Calibration curves of plotting the fluorescence intensity *versus* ALKBH5 concentrations. (C) The fluorescence intensity at 525 nm in the presence of m6A demethylases or other interferences. BSA (bovine serum albumin), PNK (T4 polynucleotide kinase), and ALP (alkaline phosphatase). ** $P < 0.01$; **** $P < 0.001$ (Student's *t*-test and all results were compared with those of the ALKBH5 group). (D) Fluorescence signal increased as concentrations of ALKBH3 increased over time ((a) 1000 nM; (b) 800 nM; (c) 650 nM; (d) 550 nM; (e) 400 nM; (f) 270 nM; (g) 135 nM; (h) 62.5 nM; (i) 0 nM; m1A₃₄₅-gRNA: 250 nM). (E) Calibration curves of ALKBH3. (F) Selectivity of the ALKBH3 biosensor. **** $P < 0.001$ (Compared with the ALKBH3 group, the *P* value was calculated by Student's *t*-test).

We directly transfected the HEK293T cells with the m1A modified gRNAs. The gene editing results and quantitative indel frequency of targeted gene loci were monitored by the Sanger sequencing method. As shown in Fig. 8A and B, after transfecting the m1A modified gRNA, the sequencing map showed almost no disturbance caused by indels. The indel frequency caused by Cas12a with m1A modified gRNAs in HEK293 cells was about 2.63%. In the negative group, an indel frequency of 0.38% was detected in cells without any gRNA. In the positive group, normal gRNA caused an indel frequency of 24.93%. These results demonstrated that the m1A modifications on the gRNA conserved region effectively inhibited the CRISPR-Cas12a activity in living cells. Moreover, we pre-treated the HEK293 cell line with an ALKBH3 demethylase overexpressed plasmid, and the m1A-modified gRNA showed an indel frequency of 17.83%, which was comparable to that of normal gRNA and the editing efficiency increased about 8 fold. Obviously, the editing ability of CRISPR-




Fig. 8 Controllable gene editing by m1A-gRNA and demethylases. (A) The results of Sanger sequencing under different conditions. The dashed lines suggest the level of disturbance as a visualization of indel formation. (B) Quantitative indel frequency of VEGAF gene loci under different conditions. The error bars show the standard deviation of three parallel experiments. **** $P < 0.0001$ was obtained by Student's *t*-test.

Cas12a was activated by the overexpressed m1A demethylase in living cells. Since there are significant differences in the content and activity of demethylases in different cells, such as cancer cells and normal cells, this strategy has the potential to be used for cell-type-specific gene editing, which is valuable for gene therapy and diagnosis.

Regulating the expression of genes based on the levels of cellular demethylases

CRISPR activation and interference have been widely used to modulate gene functions.⁴⁷ In CRISPR activation technology, a non-cleavage Cas nuclease (dCas) is coupled with a transcriptional effector to regulate target gene expression.^{48,49} Therefore, we further designed a demethylase-inducible CRISPR activation strategy (DICa), in which a transcriptional circuit with two plasmids was designed to demonstrate our strategy (Fig. 9A).⁴⁹

The HEK293 cells, which have been widely used in demethylases research as a model cell line, were used to establish the CRISPR activation system.^{31,50} As shown in Fig. 9B and C, all groups exhibited strong red fluorescence, indicating successful transfection of the dAsCas12a-VPR



plasmid (Fig. S13†) into living cells. After transfection of non-modified gRNA, the illuminating BFP signal indicated that gRNA matched to the TS-miniCMV-BFP plasmid (Fig. S14†) successfully activates the transcriptional circuit (Fig. 9B(a) and 9C(a)). In the negative group, there is no BFP expression without any gRNA in cells. In general, the m6A demethylases are overexpressed in HEK cell lines, and as a result of m6A

removal by endogenous demethylases, the m6A-deactivated gRNA could activate BFP expression similarly to the normal gRNA group (Fig. 9B(c)). We downregulated the FTO and ALKBH5 demethylases by using specific inhibitors (entacapone and IOX-1) and siRNAs, respectively. As expected, the m6A-modified gRNA cannot activate BFP expression in pre-treated HEK293 cells (Fig. 9B(d) and 9B(e)). Furthermore,





Fig. 9 Results of m6A/m1A-demethylases inducible CRISPR-dCas12a transcriptional circuits. (A) Illustration of the transcriptional circuits activated by m6A- and m1A-demethylases. The first one is a TS-miniCMV-BFP plasmid. The second plasmid is dAsCas12a-VPR which exhibited red fluorescence in cells. The third plasmid is a commercially available human ALKBH3 plasmid which shows green fluorescence in cells. The dAsCas12a-VPR plasmid produced red fluorescence after being transfected into the cell. The expression of BFP can be activated by the BFP-gRNA and dCas12-VPR complex. (B) The results of confocal laser scanning microscopy (CLSM) under different conditions. (a) BFP-gRNA + dAsCas12a-VPR plasmid + miniCMV-BFP plasmid; (b) negative group: without gRNA; (c) BFP-m6A-gRNA + dAsCas12a-VPR plasmid + miniCMV-BFP plasmid; (d) pretreated with m6A demethylase inhibitors: entacapone (80 μ M) and IOX-1 (60 μ M). (e) Pretreated with siRNA before incubating with BFP-m6A-gRNA and two plasmids. (C) The results of CLSM under different conditions. (a) BFP-gRNA + dAsCas12a-VPR plasmid + miniCMV-BFP plasmid; (b) BFP-m1A-gRNA + dAsCas12a-VPR plasmid + miniCMV-BFP plasmid; (c) only human ALKBH3 plasmid with GFP; (d) BFP-m1A-gRNA + dAsCas12a-VPR plasmid + miniCMV-BFP plasmid + human ALKBH3 plasmid with GFP; the scale bar of CLSM is 20 μ m.



an assay was performed to evaluate real-time imaging of the DICa strategy. As shown in Fig. S15,[†] the transcriptional circuit of DICa began about 6–8 h after m6A-deactivated gRNA transfection. The BFP fluorescence increased with time and reached a maximal level at 12 h.

To confirm the precise control of plasmid expression by m1A demethylase, we transfected m1A-modified gRNA into dCas12a-VPR overexpressed HEK293 cells. As shown in Fig. 9C(a) and (b), the m1A-modified gRNA did not induce blue fluorescence upon transfection. Western blot confirmed that the expression levels of ALKBH3 demethylase in the cytoplasm and nucleus of the HEK cell line are much lower than those of other demethylases (Fig. S16[†]). Then, we pre-treated the HEK293 cell line with a plasmid encoding m1A demethylase ALKBH3, and the results shown in Fig. 9C(c) and (d) demonstrate that m1A-modified gRNA with overexpressed ALKBH3 demethylase could reactivate BFP expression. A complementary technique to demonstrate the efficacy of this sensor in cells has been performed by qRT-PCR against the inducible gene. As shown in Fig. S17,[†] the mRNA level changes of BFP are consistent with the fluorescence results shown in Fig. 9. Overall, these results suggest that the methylation-deactivated CRISPR-Cas system could be specifically manipulated by the level of demethylases in cells. Naturally, an intracellular demethylase sensor based on the demethylase inducible CRISPR-Cas12a system could be established at the same time.

Conclusions

In summary, we found that both the m6A and m1A epigenetic modifications in the 5' handle of gRNA displayed efficient inhibitory effects on DNA cleavage. In addition, this regulation is highly dependent on the position and number of methylation modifications. Especially for the m1A methylation, when the sites A₃, A₄, and A₅ in the 5' handle of gRNA are modified at the same time, the deactivation efficacy reached 98%. Besides, the inhibition mechanism was tentatively analysed in this work. The methylation in the 5' handle of gRNA impedes the formation of RNPs, thereby preventing the cleavage behaviour of CRISPR-Cas12a. Moreover, a demethylase-inducible CRISPR-Cas12a tool was developed. Methylation-deactivated CRISPR-Cas12a displayed remarkable cleavage activity in the presence of demethylases. ALKBH5 and FTO demethylases can effectively activate the m6A-deactivated CRISPR-Cas12a. ALKBH3 demethylase can selectively activate m1A-deactivated CRISPR-Cas12a. The exceptional performance of DIC-Cas12a enables us to develop *in vitro* sensor strategies with a high degree of sensitivity. Due to these unique advantages, we further proposed a demethylase-inducible CRISPR activation strategy and demethylase-inducible gene editing strategy, which enabled plasmid gene expression in living cells to be activated and gene editing to be controlled. Specifically, m6A modified gRNA and m1A modified gRNA displayed different results in HEK293T cell lines. The m6A modified gRNA could directly activate the BFP gene expression in HEK293. In contrast, m1A-modified sgRNA requires a large amount of exogenous demethylase to activate the target gene in HEK293 cells. These

results suggested that our demethylase-inducible CRISPR system could respond to specific cells according to the level of cellular demethylases. As for the limitations of this strategy, according to current experimental findings, m6A-modified gRNA exhibits lower stability in cells compared to m1A-modified gRNA, and its blocking efficiency is only 70% *in vitro*, which is significantly lower than the 98% blocking efficiency of m1A-modified gRNA. Besides, compared with unnatural nucleotide modifications, such as 2'-F and phosphorothioates, natural methylation modifications cannot effectively prevent the degradation of gRNA by RNase in cells. Despite these limitations, we believe that exploring the methylation effect on emerging Cas proteins, such as Cas13d and Cas12f, could expand the potential therapeutic applications of this strategy.

Author contributions

Zhian Hu and Ao Sun planned and completed all experiments in this work. Zhian Hu and Ao Sun contributed equally. Jinlei Yang and Gongwei Sun assisted in some experiments, including cell experiments and CLSM detection. Gu Naz gave suggestions for some experiments and helped in article polishing. This manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Conflicts of interest

The authors declare no competing financial interest.

Acknowledgements

We thank the Metabolomics Facility Center in the National Protein Science Technology Center of Tsinghua University for HPLC-MS/MS experiments. And we thank VectorBuilder Inc. (Guangzhou, China) for plasmid construction. We thank the Home for Researchers editorial team (<https://www.home-for-researchers.com/>) for language editing service. We thank Huasong Ai for assistance in EMSA experiments. This work was supported by the National Natural Science Foundation of China (Nos. 21974078, 21727813, and 22074077), National Science and Technology Major Project of the Ministry of Science and Technology of China (2022YFF0710200) and Fundamental Research Funds for the Central Universities (FRF-TP-22-022A1).

Notes and references

- 1 R. Torres-Ruiz and S. Rodriguez-Perales, CRISPR-Cas9 technology: applications and human disease modelling, *Briefings Funct. Genomics*, 2017, **16**, 4–12.
- 2 J. A. Doudna and E. Charpentier, Genome editing. The new frontier of genome engineering with CRISPR-Cas9, *Science*, 2014, **346**, 1258096.



- 3 X. Dai, X. Chen, Q. Fang, J. Li and Z. Bai, Inducible CRISPR genome-editing tool: classifications and future trends, *Crit. Rev. Biotechnol.*, 2018, **38**, 573–586.
- 4 P. K. Jain, V. Ramanan, A. G. Schepers, N. S. Dalvie, A. Panda, H. E. Fleming and S. N. Bhatia, Development of Light-Activated CRISPR Using Guide RNAs with Photocleavable Protectors, *Angew. Chem., Int. Ed. Engl.*, 2016, **55**, 12440–12444.
- 5 Y. Nihongaki, F. Kawano, T. Nakajima and M. Sato, Photoactivatable CRISPR-Cas9 for optogenetic genome editing, *Nat. Biotechnol.*, 2015, **33**, 755–760.
- 6 L. E. Dow, J. Fisher, K. P. O'Rourke, A. Muley, E. R. Kasthuber, G. Livshits, D. F. Tschaharganeh, N. D. Socci and S. W. Lowe, Inducible *in vivo* genome editing with CRISPR-Cas9, *Nat. Biotechnol.*, 2015, **33**, 390–394.
- 7 K. I. Liu, M. N. Ramli, C. W. Woo, Y. Wang, T. Zhao, X. Zhang, G. R. Yim, B. Y. Chong, A. Gowher, M. Z. Chua, J. Jung, J. H. Lee and M. H. Tan, A chemical-inducible CRISPR-Cas9 system for rapid control of genome editing, *Nat. Chem. Biol.*, 2016, **12**, 980–987.
- 8 S. R. Wang, L. Y. Wu, H. Y. Huang, W. Xiong, J. Liu, L. Wei, P. Yin, T. Tian and X. Zhou, Conditional control of RNA-guided nucleic acid cleavage and gene editing, *Nat. Comm.*, 2020, **11**, 91.
- 9 X. W. Wang, L. F. Hu, J. Hao, L. Q. Liao, Y. T. Chiu, M. Shi and Y. Wang, A microRNA-inducible CRISPR-Cas9 platform serves as a microRNA sensor and cell-type-specific genome regulation tool, *Nat. Cell Biol.*, 2019, **21**, 522–530.
- 10 C. Gu, L. Xiao, J. Shang, X. Xu, L. He and Y. Xiang, Chemical synthesis of stimuli-responsive guide RNA for conditional control of CRISPR-Cas9 gene editing, *Chem. Sci.*, 2021, **12**, 9934–9945.
- 11 Y. Fu, J. D. Sander, D. Reyon, V. M. Cascio and J. K. Joung, Improving CRISPR-Cas nuclease specificity using truncated guide RNAs, *Nat. Biotechnol.*, 2014, **32**, 279–284.
- 12 E. Rozners, Chemical Modifications of CRISPR RNAs to Improve Gene-Editing Activity and Specificity, *J. Am. Chem. Soc.*, 2022, **144**, 12584–12594.
- 13 W. Zhou, W. Brown, A. Bardhan, M. Delaney, A. S. Ilk, R. R. Rauen, S. I. Kahn, M. Tsang and A. Deiters, Spatiotemporal Control of CRISPR/Cas9 Function in Cells and Zebrafish using Light-Activated Guide RNA, *Angew. Chem., Int. Ed. Engl.*, 2020, **59**, 8998–9003.
- 14 B. Li, W. Zhao, X. Luo, X. Zhang, C. Li, C. Zeng and Y. Dong, Engineering CRISPR-Cpf1 crRNAs and mRNAs to maximize genome editing efficiency, *Nat. Biomed. Eng.*, 2017, **1**, 66.
- 15 M. A. McMahon, T. P. Prakash, D. W. Cleveland, C. F. Bennett and M. Rahdar, Chemically Modified Cpf1-CRISPR RNAs Mediate Efficient Genome Editing in Mammalian Cells, *Mol. Ther.*, 2018, **26**, 1228–1240.
- 16 A. R. Krysler, C. R. Cromwell, T. Tu, J. Jovel and B. P. Hubbard, Guide RNAs containing universal bases enable Cas9/Cas12a recognition of polymorphic sequences, *Nat. Comm.*, 2022, **13**, 1617.
- 17 C. R. Cromwell, K. Sung, J. Park, A. R. Krysler, J. Jovel, S. K. Kim and B. P. Hubbard, Incorporation of bridged nucleic acids into CRISPR RNAs improves Cas9 endonuclease specificity, *Nat. Comm.*, 2018, **9**, 1448.
- 18 E. A. Ageely, R. Chilamkurthy, S. Jana, L. Abdullahu, D. O'Reilly, P. J. Jensik, M. J. Damha and K. T. Gagnon, Gene editing with CRISPR-Cas12a guides possessing ribose-modified pseudoknot handles, *Nat. Comm.*, 2021, **12**, 6591.
- 19 S. Wang, L. Wei, J. Q. Wang, H. Ji, W. Xiong, J. Liu, P. Yin, T. Tian and X. Zhou, Light-Driven Activation of RNA-Guided Nucleic Acid Cleavage, *ACS Chem. Biol.*, 2020, **15**, 1455–1463.
- 20 Y. Wang, Y. Liu, F. Xie, J. Lin and L. Xu, Photocontrol of CRISPR/Cas9 function by site-specific chemical modification of guide RNA, *Chem. Sci.*, 2020, **11**, 11478–11484.
- 21 D. Zhang, L. Liu, S. Jin, E. Tota, Z. Li, X. Piao, X. Zhang, X. D. Fu and N. K. Devaraj, Site-Specific and Enzymatic Cross-Linking of sgRNA Enables Wavelength-Selectable Photoactivated Control of CRISPR Gene Editing, *J. Am. Chem. Soc.*, 2022, **144**, 4487–4495.
- 22 M. Habibian, C. McKinlay, T. R. Blake, A. M. Kietrys, R. M. Waymouth, P. A. Wender and E. T. Kool, Reversible RNA acylation for control of CRISPR-Cas9 gene editing, *Chem. Sci.*, 2019, **11**, 1011–1016.
- 23 P. Jones, Functions of DNA methylation: islands, start sites, gene bodies and beyond, *Nat. Rev. Genet.*, 2012, **29**(13), 484–492.
- 24 J. S. Kim, Genome editing comes of age, *Nat. Protoc.*, 2016, **11**, 1573–1578.
- 25 J. J. Liu, N. Orlova, B. L. Oakes, E. Ma, H. B. Spinner, K. L. M. Baney, J. Chuck, D. Tan, G. J. Knott, L. B. Harrington, B. Al-Shayeb, A. Wagner, J. Brötzmann, B. T. Staahl, K. L. Taylor, J. Desmarais, E. Nogales and J. A. Doudna, CasX enzymes comprise a distinct family of RNA-guided genome editors, *Nature*, 2019, **566**, 218–223.
- 26 J. Song and C. Yi, Chemical Modifications to RNA: A New Layer of Gene Expression Regulation, *ACS Chem. Biol.*, 2017, **12**, 316–325.
- 27 S. Zaccara, R. J. Ries and S. R. Jaffrey, Reading, writing and erasing mRNA methylation, *Nat. Rev. Mol. Cell Biol.*, 2019, **20**, 608–624.
- 28 D. V. Prokhorova, I. P. Vokhtantsev, P. O. Tolstova, E. S. Zhuravlev, L. M. Kulishova, D. O. Zharkov and G. A. Stepanov, Natural Nucleoside Modifications in Guide RNAs Can Modulate the Activity of the CRISPR-Cas9 System In Vitro, *CRISPR J.*, 2022, **5**, 799–812.
- 29 I. Barbieri and T. Kouzarides, Role of RNA modifications in cancer, *Nat. Rev. Cancer*, 2020, **20**, 303–322.
- 30 G. Jia, Y. Fu, X. Zhao, Q. Dai, G. Zheng, Y. Yang, C. Yi, T. Lindahl, T. Pan, Y. G. Yang and C. He, N₆-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO, *Nat. Chem. Biol.*, 2011, **7**, 885–887.
- 31 G. Zheng, J. A. Dahl, Y. Niu, P. Fedorcsak, C. M. Huang, C. J. Li, C. B. Vågbo, Y. Shi, W. L. Wang, S. H. Song, Z. Lu, R. P. Bosmans, Q. Dai, Y. J. Hao, X. Yang, W. M. Zhao, W. M. Tong, X. J. Wang, F. Bogdan, K. Furu, Y. Fu, G. Jia,



- X. Zhao, J. Liu, H. E. Krokan, A. Klungland, Y. G. Yang and C. He, ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility, *Mol. Cell*, 2013, **49**, 18–29.
- 32 X. Li, X. Xiong, K. Wang, L. Wang, X. Shu, S. Ma and C. Yi, Transcriptome-wide mapping reveals reversible and dynamic N(1)-methyladenosine methylome, *Nat. Chem. Biol.*, 2016, **12**, 311–316.
- 33 I. A. Roundtree, M. E. Evans, T. Pan and C. He, Dynamic RNA Modifications in Gene Expression Regulation, *Cell*, 2017, **169**, 1187–1200.
- 34 T. Yamano, B. Zetsche, R. Ishitani, F. Zhang, H. Nishimasu and O. Nureki, Structural Basis for the Canonical and Non-canonical PAM Recognition by CRISPR-Cpf1, *Mol. Cell*, 2017, **67**, 633–645.
- 35 C. Roost, S. R. Lynch, P. J. Batista, K. Qu, H. Y. Chang and E. T. Kool, Structure and thermodynamics of N₆-methyladenosine in RNA: a spring-loaded base modification, *J. Am. Chem. Soc.*, 2015, **137**, 2107–2115.
- 36 S. Stella, P. Mesa, J. Thomsen, B. Paul, P. Alcón, S. B. Jensen, B. Saligram, M. E. Moses, N. S. Hatzakis and G. Montoya, Conformational Activation Promotes CRISPR-Cas12a Catalysis and Resetting of the Endonuclease Activity, *Cell*, 2018, **175**, 1856–1871.
- 37 K. I. Zhou, M. Parisien, Q. Dai, N. Liu, L. Diatchenko, J. R. Sachleben and T. Pan, N(6)-Methyladenosine Modification in a Long Noncoding RNA Hairpin Predisposes Its Conformation to Protein Binding, *J. Mol. Biol.*, 2016, **428**, 822–833.
- 38 Y. Chen, S. Yang, S. Peng, W. Li, F. Wu, Q. Yao, F. Wang, X. Weng and X. Zhou, N1-Methyladenosine detection with CRISPR-Cas13a/C2c2, *Chem. Sci.*, 2019, **10**, 2975–2979.
- 39 J. S. Chen, E. Ma, L. B. Harrington, M. Da Costa, X. Tian, J. M. Palefsky and J. A. Doudna, CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity, *Science*, 2018, **360**, 436–439.
- 40 E. M. Anderson, A. Haupt, J. A. Schiel, E. Chou, H. B. Machado, Ž. Strezoska, S. Lenger, S. McClelland, A. Birmingham, A. Vermeulen and A. Smith, Systematic analysis of CRISPR-Cas9 mismatch tolerance reveals low levels of off-target activity, *J. Biotechnol.*, 2015, **211**, 56–65.
- 41 Y. Tang and Y. Fu, Class 2 CRISPR/Cas: an expanding biotechnology toolbox for and beyond genome editing, *Cell Biosci.*, 2018, **8**, 59.
- 42 J. C. Cofsky, D. Karandur, C. J. Huang, I. P. Witte, J. Kuriyan and J. A. Doudna, CRISPR-Cas12a exploits R-loop asymmetry to form double-strand breaks, *Elife*, 2020, **9**, 55143.
- 43 A. Cheong, J. J. A. Low, A. Lim, P. M. Yen and E. C. Y. Woon, A fluorescent methylation-switchable probe for highly sensitive analysis of FTO N₆(6)-methyladenosine demethylase activity in cells, *Chem. Sci.*, 2018, **9**, 7174–7185.
- 44 Q. Wang, K. Tan, H. Wang, J. Shang, Y. Wan, X. Liu, X. Weng and F. Wang, Orthogonal Demethylase-Activated Deoxyribozyme for Intracellular Imaging and Gene Regulation, *J. Am. Chem. Soc.*, 2021, **143**, 6895–6904.
- 45 X. Wang, X. Yi, Z. Huang, J. He, Z. Wu, X. Chu and J. H. Jiang, Repaired and Activated DNAzyme Enables the Monitoring of DNA Alkylation Repair in Live Cells, *Angew. Chem., Int. Ed. Engl.*, 2021, **60**, 19889–19896.
- 46 B. Zetsche, M. Heidenreich, P. Mohanraju, I. Fedorova, J. Kneppers, E. M. DeGennaro, N. Winblad, S. R. Choudhury, O. O. Abudayyeh, J. S. Gootenberg, W. Y. Wu, D. A. Scott, K. Severinov, J. van der Oost and F. Zhang, Multiplex gene editing by CRISPR-Cpf1 using a single crRNA array, *Nat. Biotechnol.*, 2017, **35**, 31–34.
- 47 M. Kampmann, CRISPRi and CRISPRa Screens in Mammalian Cells for Precision Biology and Medicine, *ACS Chem. Biol.*, 2018, **13**, 406–416.
- 48 T. I. Jensen, N. S. Mikkelsen, Z. Gao, J. Foßelteder, G. Pabst, E. Axelgaard, A. Laustsen, S. König, A. Reinisch and R. O. Bak, Targeted regulation of transcription in primary cells using CRISPRa and CRISPRi, *Genome Res.*, 2021, **31**, 2120–2130.
- 49 Z. M. Ying, F. Wang, X. Chu, R. Q. Yu and J. H. Jiang, Activatable CRISPR Transcriptional Circuits Generate Functional RNA for mRNA Sensing and Silencing, *Angew. Chem., Int. Ed. Engl.*, 2020, **59**, 18599–18604.
- 50 J. Wei, F. Liu, Z. Lu, Q. Fei, Y. Ai, P. C. He, H. Shi, X. Cui, R. Su, A. Klungland, G. Jia, J. Chen and C. He, Differential m(6)A, m(6)A(m), and m(1)A Demethylation Mediated by FTO in the Cell Nucleus and Cytoplasm, *Mol. Cell*, 2018, **71**, 973–985.

